放射疗法与免疫检查点阻断：2016年概览
Radiotherapy and immune checkpoint blockades: a snapshot in 2016.
作者信息
Koo Taeryool, Kim In Ah
机构信息
Department of Radiation Oncology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Radiat Oncol J. 2016 Dec;34(4):250-259. doi: 10.3857/roj.2016.02033. Epub 2016 Dec 28.
Abstract
Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.
摘要
包括细胞毒性T淋巴细胞抗原4（CTLA-4）、程序性死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）的单克隆抗体（mAb）在内的免疫检查点阻断剂已成为一种有前景的抗癌疗法。几种免疫检查点阻断剂已获得美国食品药品监督管理局（FDA）的批准，并在晚期黑色素瘤和非小细胞肺癌患者的临床试验中取得了显著成功。放疗因其强大的促免疫作用，是免疫检查点阻断剂的一个有前景的联合治疗伙伴。本综述将基于现有的临床前和临床数据，涵盖放疗与免疫检查点阻断剂联合应用的当前问题和未来前景。
相似文献
1
Radiotherapy and immune checkpoint blockades: a snapshot in 2016.放射疗法与免疫检查点阻断：2016年概览
Radiat Oncol J. 2016 Dec;34(4):250-259. doi: 10.3857/roj.2016.02033. Epub 2016 Dec 28.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
[Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].[使用免疫检查点阻断剂治疗黑色素瘤的最新进展]
Gan To Kagaku Ryoho. 2016 Jun;43(6):661-5.
4
PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.PD-1/PD-L1 检查点阻断在非小细胞肺癌中的应用：新进展与挑战。
Cancer Lett. 2017 Oct 1;405:29-37. doi: 10.1016/j.canlet.2017.06.033. Epub 2017 Jul 6.
5
Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.肿瘤微环境靶向纳米医学递药方法的最新进展，以克服基于免疫检查点阻断的免疫疗法的局限性。
J Control Release. 2021 Apr 10;332:109-126. doi: 10.1016/j.jconrel.2021.02.002. Epub 2021 Feb 8.
6
[Development of immune checkpoint inhibitors].[免疫检查点抑制剂的研发]
Rinsho Ketsueki. 2017;58(8):966-976. doi: 10.11406/rinketsu.58.966.
7
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.用于非小细胞肺癌治疗的免疫检查点抑制剂。
J Chin Med Assoc. 2017 Jan;80(1):7-14. doi: 10.1016/j.jcma.2016.08.005. Epub 2016 Sep 29.
8
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.PD-1 或 PD-L1 抑制剂联合治疗癌症。
Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23.
9
Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.免疫检查点抑制剂在非小细胞肺癌中的应用：鸟瞰全局。
Life Sci. 2019 Sep 15;233:116713. doi: 10.1016/j.lfs.2019.116713. Epub 2019 Aug 3.
10
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.PD-1/PD-L1 检查点阻断免疫疗法中的预测生物标志物。
Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10.
引用本文的文献
1
Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study.术后原发区域放疗对新发转移性乳腺癌生存的影响：一项回顾性研究
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251341195. doi: 10.1177/15330338251341195. Epub 2025 May 7.
2
Integration of immune and hypoxia gene signatures improves the prediction of radiosensitivity in breast cancer.免疫和缺氧基因特征的整合改善了乳腺癌放射敏感性的预测。
Am J Cancer Res. 2022 Mar 15;12(3):1222-1240. eCollection 2022.
3
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints.肿瘤微环境中免疫细胞与免疫检查点介导的代谢重编程
Front Oncol. 2021 Nov 11;11:759015. doi: 10.3389/fonc.2021.759015. eCollection 2021.
4
Upfront radiosurgery plus targeted agents followed by active brain control using radiosurgery delays neurological death in non-small cell lung cancer with brain metastasis. upfront 立体定向放射外科手术联合靶向药物治疗，随后采用立体定向放射外科手术进行主动脑控制，可延迟伴脑转移的非小细胞肺癌患者的神经死亡。
Clin Exp Metastasis. 2020 Apr;37(2):353-363. doi: 10.1007/s10585-020-10022-6. Epub 2020 Feb 1.
5
Radiation therapy and immunotherapy-a potential combination in cancer treatment.放射治疗与免疫治疗——癌症治疗中的一种潜在联合疗法。
Curr Oncol. 2018 Oct;25(5):e454-e460. doi: 10.3747/co.25.4002. Epub 2018 Oct 31.
6
Novel biological strategies to enhance the radiation therapeutic ratio.提高放射治疗比率的新型生物学策略。
Radiat Oncol J. 2018 Sep;36(3):172-181. doi: 10.3857/roj.2018.00332. Epub 2018 Sep 30.
7
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.RNAi 介导的β-连环蛋白抑制与免疫检查点阻断联合促进 T 细胞浸润和抗肿瘤活性。
Mol Ther. 2018 Nov 7;26(11):2567-2579. doi: 10.1016/j.ymthe.2018.09.005. Epub 2018 Sep 13.
8
Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma.纳武利尤单抗联合放疗治疗颅外转移性恶性黑色素瘤。
Jpn J Radiol. 2018 Dec;36(12):712-718. doi: 10.1007/s11604-018-0774-8. Epub 2018 Sep 11.
9
Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients.低分割放疗联合抗PD-1单药治疗对难治性晚期黑色素瘤患者的疗效
Oncoimmunology. 2018 Mar 13;7(7):e1442166. doi: 10.1080/2162402X.2018.1442166. eCollection 2018.
10
Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects.立体定向体部放射治疗联合不成熟树突状细胞疫苗接种增强局部和全身效应。
Cancer Res Treat. 2019 Apr;51(2):464-473. doi: 10.4143/crt.2018.186. Epub 2018 Jun 6.
本文引用的文献
1
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.在直肠腺癌患者中，PD-L1 由放化疗上调，并与良好的预后相关。
Eur J Cancer. 2016 Sep;65:52-60. doi: 10.1016/j.ejca.2016.06.015. Epub 2016 Jul 25.
2
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.帕博利珠单抗治疗晚期黑色素瘤患者的肿瘤应答与生存关系。
JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059.
3
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
4
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.食管鳞癌患者新辅助同步放化疗后程序性死亡配体1的肿瘤表达变化
Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.
5
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
6
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.帕博利珠单抗对比研究者选择的化疗用于伊匹单抗难治性黑色素瘤（KEYNOTE-002）：一项随机、对照、2期试验
Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.
7
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
8
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
9
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.靶向T细胞上的抑制性受体CTLA-4可增强小鼠间皮瘤模型中的远隔效应。
Oncotarget. 2015 May 20;6(14):12468-80. doi: 10.18632/oncotarget.3487.
10
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.帕博利珠单抗（MK-3475；抗 PD-1 单克隆抗体）治疗晚期实体瘤患者的 I 期研究。
Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.
Zotero 插件